X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OLX75016 It is being developed as a novel treatment approach for metabolic dysfunctions associated with non-alcoholic fatty liver disease linked to obesity.
Lead Product(s): OLX75016
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX75016
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
The company has received approval from the Alfred Human Research Ethics Committee to conduct a Phase 1 clinical trial of drug candidate OLX75016 for the treatment of non-alcohol steatohepatitis.
Lead Product(s): OLX75016
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX75016
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
OLX10212 is a VEGF Modulator oligonucleotide drug administered via intravitreal injection, currently being investigated for the treatment of Age-Related Macular Degeneration.
Lead Product(s): OLX10212
Therapeutic Area: Ophthalmology Product Name: OLX10212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
OLX72021 an investigational RNAi therapeutic and acts to suppress the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor (AR).
Lead Product(s): OLX72021
Therapeutic Area: Dermatology Product Name: OLX72021
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
Companies signed a memorandum of understanding, for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum.
Lead Product(s): RNA-based Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: DynamiCure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
OLX10010 is an asymmetric siRNA duplex with a cell-penetrating moiety attached to the 3’ of sense strand (cell-penetrating asymmetric siRNA, i.e. cp-asiRNA), targeting human connective tissue growth factor, which is a key factor in the development of hypertrophic scars.
Lead Product(s): OLX10010
Therapeutic Area: Dermatology Product Name: OLX101A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
OLX10212, an investigational RNAi therapeutic intended for the treatment of AMD. It targets inflammation pathways (blockade of VEGF) and offers increased specificity over conventional siRNA having the additional benefit of impermanence over gene therapy.
Lead Product(s): OLX10212
Therapeutic Area: Ophthalmology Product Name: OLX10212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
OLX72021 acts to suppress the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor (AR)
Lead Product(s): OLX72021
Therapeutic Area: Dermatology Product Name: OLX72021
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
OLX104C reduces the expression of androgen receptor (AR), one of the key factors that cause androgenetic alopecia, which results in the suppression of the hair cycle transition from anagen to telogen phase.
Lead Product(s): OLX104C
Therapeutic Area: Dermatology Product Name: OLX104C
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
The OLX702A program is based on compelling human genetic evidence which suggests that knockdown of this target may reduce liver fat, inflammation, and fibrosis and protect against liver-related mortality.
Lead Product(s): OLX702A
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX702A
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
